Structure via PubChem · Public domain (PubChem)
fentiazac
Sign in to saveAlso known as Fentiazaco, Fentiazacum, 4-(p-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid, 4-(4-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid
Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain. Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.
Chemical data
- Formula
- C17H12ClNO2S
- Molecular weight
- 329.8 g/mol
- IUPAC name
- 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid
- SMILES
- C1=CC=C(C=C1)C2=NC(=C(S2)CC(=O)O)C3=CC=C(C=C3)Cl
- InChIKey
- JIEKMACRVQTPRC-UHFFFAOYSA-N
- XLogP
- 5.2
- Polar surface area
- 78.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- Myalgia, Arthralgia, rheumatic disease
via ChEMBL · EBI
Research
58 papers- Fentiazac in the treatment of osteoarthritis and tendinitis.Current medical research and opinion · 1983
- Metabolism of fentiazac.Arzneimittel-Forschung · 1980
- Fentiazac in rheumatoid arthritis: comparison with sulindac and long-term tolerance.Current medical research and opinion · 1983
- Fentiazac as a therapeutic aid in the treatment of tuberculosis.The Journal of international medical research · 1977
- Fentiazac in osteoarthritis: comparison of BID and QID regimens.Clinical therapeutics · 1983
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 329.028
Show 5 more facts
- chemical formula
- C₁₇H₁₂ClNO₂S
- canonical SMILES
- C1=CC=C(C=C1)C2=NC(=C(S2)CC(=O)O)C3=CC=C(C=C3)Cl
- subject has role
- non-steroidal anti-inflammatory drug
- MCN code
- 2934.10.10
- Commons category
- Fentiazac
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain. Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.
Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.
Excerpted from Wikipedia’s “fentiazac” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0